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INTRACELLULAR LOCALIZATION AND EFFECTS OF THE TRACE–AMINE 
ASSOCIATED RECEPTOR 1 
 
SHANE SHAKAR SCOTT 
ABSTRACT 
 
The trace amine–associated receptor 1 (TAAR1) is an intracellular G–protein 
coupled receptor whose activation by trace amines, catecholamines and amphetamines 
leads to elevation of cyclic–AMP and activation of protein kinase A (PKA). Recently, the 
Amara lab discovered that TAAR1 also mediates the activation of the small GTPase, 
RhoA. TAAR1 is expressed in midbrain dopamine (DA) neurons, including those in the 
substantia nigra and ventral tegmental area, and thus is positioned to modulate both motor 
activity and addiction–related plasticity. Due to antibody limitations, however, neither the 
intracellular membrane localization of TAAR1 nor the site of signaling by this receptor 
has been clearly demonstrated in neurons.  
Dopaminergic neurotransmission is a coordinated process which requires 
synthesis, packaging, exocytosis, and reuptake of DA. Amphetamine (AMPH) can 
stimulate TAAR1, which has been shown to downregulate the surface expression of the 
dopamine transporter, thus decreasing DA reuptake and increasing extracellular DA 
concentrations. In addition, AMPH and elevation of cAMP decreases the activity of the 
vesicular monoamine transporter, VMAT2 in neurosecretory pheochromocytoma (PC12) 
cells, although the mechanism of this regulation remains undefined. The co–expression of 
TAAR1 and VMAT2 in the DA neuron and PC12 cells suggests that TAAR1 activation 
  viii 
may mediate the effects of AMPH/cAMP on VMAT2. Towards understanding the role of 
TAAR1 in transporter trafficking and function in the DA neuron, this thesis seeks to 
define the mechanism of AMPH action on TAAR1 signaling and examine the 
intracellular membrane localization and pathways downstream of TAAR1 activation.  
In Chapter I, we used compartment–specific FRET–based sensors to determine 
the functional subcellular localization of TAAR1. Novel endomembrane targeting 
constructs were designed and targeting, and functionality was confirmed using standard 
biochemical techniques and confocal microscopy. Targeted FRET–based sensors for 
PKA and RhoA activation enabled us to assess TAAR1–mediated responses to AMPH 
treatment in discrete subcellular compartments. AMPH increased PKA activation in the 
synaptic vesicle compartment. However, TAAR1–mediated effects of AMPH on RhoA 
signaling was differentially localized to the Golgi and ER membrane compartments.  
In Chapter II, it was hypothesized that PKA activation of TAAR1 may negatively 
regulate VMAT2. We used midbrain DA neuron cultures and SK–N–SH neuroblastoma 
cells that express TAAR1 and VMAT2 and release catecholamines as model systems. 
With CRISPR–Cas9 technology the Amara lab generated TAAR1 knockout SK–N–SH 
cells that were used to examine the role of TAAR1 in VMAT2 regulation. VMAT2–
mediated uptake of radiolabeled DA and serotonin was measured in the presence or 
absence of drugs that modulate VMAT2 activity. Inhibition of the Gα stimulatory (GαS) 
G–proteins upstream of PKA activation increased VMAT2 uptake; conversely, 
stimulation of cAMP decreased VMAT2 activity. Compared to wildtype cells, we found 
no difference in VMAT2 uptake in TAAR1 knockout cells treated with PKA agonists like 
  ix 
dibutryl cAMP and forskolin. These data suggest that VMAT2 uptake is modulated by 
GαS signaling, cAMP and PKA activation, but does not require TAAR1. Taken together 
our results show that the cAMP–dependent inhibition of VMAT2 uptake by PKA is not 
mediated by the TAAR1 receptor.   
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CHAPTER ONE: INTRODUCTION   
Historical Background 
The simultaneous discovery of the novel trace amine–associated receptor 1 
(TAAR1) by two independent groups in 2001 opened doors to deciphering the roles of 
endogenous trace amines (TAs) in the monoaminergic systems (Figure 1.1A) [1,2]. 
TAAR1, a phylogenetically conserved G–protein coupled receptor  (GPCR), is activated 
by TAs like ρ–tyramine, β–phenylethylamine (β–PEA), octopamine and tryptamine [3]. 
TAs are present in trace amounts in the mammalian brain and share structural and 
metabolic similarities with classic monoamines including DA, which is also a TAAR1 
agonist [1–3]. Like DA, TA’s are also degraded by monoamine oxidase (MAO) enzymes 
(Figure 1.1B) [4,5]. Prior to TAAR1’s discovery, initial studies linked TAs to increased 
sympathomimetic actions in the peripheral nervous system (PNS) where TAs modulated 
the release of norepinephrine (NE) in peripheral synapses [6,7]. The consequence of 
excessive ρ–tyramine extracellular release of NE results in a hypertensive crisis called the 
“tyramine storm,” experienced by patients who consume copious amounts of aged cheese 
containing ρ–tyramine while adhering to treatments with monoamine oxidase inhibitors 
that would normally degrade tyramine (Figure 1.1B) [6–8].  
TAAR1 expression  
TAAR1 mRNA and protein is expressed in the central nervous system (CNS), 
albeit in low levels compared to the PNS [1,2,9–11]. Using quantitative polymerase chain 
reaction (qPCR) analysis and mRNA in situ hybridization studies, Bunzow and 
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colleagues showed that TAAR1 mRNA was expressed in the monoaminergic nuclei of 
locus coeruleus, nucleus accumbens (NAc), prefrontal cortex (PFC), ventral tegmental 
area (VTA), and substantia nigra (SN) [2]. Later, using a LacZ–driven reporter for 
TAAR1 it was demonstrated that TAAR1 protein is also present in hypothalamus, 
amygdala, preoptic area and dorsal raphe nucleus [9]. Surprisingly, TAAR1 was also 
shown to be predominately localized intracellularly, and it appeared to be coupled to Gα 
stimulatory (GαS) heterotrimeric G–proteins [1,2,11]. This knowledge prompted the 
search for TAAR1’s intracellular membrane localization. Work by Szumska and 
colleagues described that in thyrocytes, TAAR1 is present in membranes of subcellular 
compartments that function in the secretory pathway as well as, in the apical plasma 
membrane [12]. Using TAAR1 specific antibodies, it was shown that TAAR1 localized 
to the endoplasmic reticulum (ER), the Golgi apparatus, and transport vesicle–like 
structures that lined up along the borders of neighboring thyrocytes but was absent from 
endosomal vesicles [12]. However, the subcellular and functional localization of TAAR1 
in neurons remains unknown due to both the limitations of the antibodies as well as, low 
levels of TAAR1 protein expression in brain [1,2]. 
TAAR1 activation and behavior 
Along with TAs, the biogenic amines and psychostimulants, including dopamine 
(DA), methamphetamine (METH), and amphetamine (AMPH), also activate TAAR1 
[1,2,10,13]. In a subset of DA neurons in murine and primate brain TAAR1 is expressed 
with DAT [13]. Accordingly, animal behavior studies implicate TAAR1 as a 
neuromodulator of DA neurotransmission in the mesolimbic pathway, where activation 
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of  TAAR1 inhibits DA neuron firing [9,14]. TAAR1 contributes to the pathophysiology 
and addictive properties of amphetamine type drugs and modulates the degeneration of 
DA neurons [15]. TAAR1 knockout mice are hypersensitive to AMPH, as measured by 
intracerebral microdialysis, where administration of AMPH increased extracellular DA 
and norepinephrine levels compared to wildtype mice [9,16]. Activation of TAAR1 by 
METH results in inhibition of DA uptake and DA efflux through the DAT transporter 
[10,13]. Furthermore, inhibition of TAAR1 by antagonists, increases the rate of cocaine 
and METH self–administration and promotes relapse of this addictive behavior [17,18]. 
In this regard, TAAR1 represents a potential therapeutic target for treatment of AMPH 
and METH drug addiction.   
TAAR1 in transporter and receptor membrane localization  
Xie and Miller first demonstrated the role of TAAR1 in regulation of dopamine 
transporter (DAT) trafficking and surface expression in 2009 [13]. TAAR1 knockout 
mice treated with AMPH lost the ability to internalize DAT [13].  Wheeler and Underhill 
later showed that DAT internalization required AMPH–mediated activation of a small 
GTPase, RhoA and its reciprocal inactivation by PKA [19]. Recently, the Amara lab 
demonstrated that TAAR1 activation by AMPH is responsible for increased RhoA 
signaling and DAT internalization (unpublished).  In human embryonic kidney 293 
(HEK293) and SK–N–SH neuroblastoma cells transiently transfected with DAT, AMPH–
induced DAT internalization is abolished in the absence of TAAR1 (unpublished). 
Glutamate receptors and transporters in neurons of the striatum are also regulated by 
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TAAR1, suggesting that DA is not the only neurotransmitter system affected in AMPH 
drug sensitization and addiction [15,20]. For example, Underhill and colleagues showed 
that AMPH induces internalization of the excitatory amino acid transporter 3 (EAAT3) 
[21],  which increases glutamate N–methyl–D–aspartate (NMDA) receptor mediated 
synaptic currents in the VTA and substantia nigra pars compacta [22]. Additionally, 
changes in NMDA and α–amino–3–hydroxy–5–methyl–4–isoxazolepropionic acid 
(AMPA) receptor compositions have been reported in the striatum of TAAR1 KO mice 
treated with AMPH [15,20].  
TAAR1 agonist–induced PKA and RhoA signaling  
TAAR1 couples to GαS [1,2] and Gα13 (unpublished) heterotrimeric G–proteins. 
Activation of TAAR1 leads to activation of the GαS G–protein and stimulates adenylate 
cyclase (AC), which catalyzes the formation of cyclic–AMP from adenosine triphosphate 
(ATP). The increase in cAMP activates protein kinase A (PKA) signaling [1,2]. Use of 
PKA–based FRET sensors by the Amara lab showed that TAAR1 is the intracellular 
target of AMPH responsible for the increases in PKA activation (unpublished). Notably, 
TAAR1 is also coupled to Gα13 G–proteins that are responsible for activation of RhoA 
(unpublished). TAAR1–mediated activation of RhoA in response to AMPH is also 
responsible for DAT and EAAT3 internalization (unpublished). Current data suggest that 
DAT dependent entry of AMPH into the cell leads to the activation of Gα13 coupled 
TAAR1 receptors (unpublished) and elevates RhoA signaling as well as GαS–PKA 
activation [19]. TAAR1–mediated activation of PKA in response to AMPH inactivates 
RhoA signaling [19]. Therefore, AMPH action on internalization requires a balance of 
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RhoA activation and PKA–dependent RhoA inactivation that are both mediated by 
TAAR1 [19]. 
Components of PKA and RhoA signaling are localized to discrete compartments  
The ability of TAAR1 to activate both RhoA and PKA signaling is presumed to 
be dependent on the ability of GPCRs to adopt various conformational states [23,24]. 
TAAR1 is associated with an intracellular membrane and largely absent from the plasma 
membrane of transfected cells [25], indicating that the signaling components of TAAR1 
maybe localized to a specific membrane compartment of the cell. The predominant 
models of GαS–AC–cAMP require diffusion of cAMP from the plasma–membrane 
activated AC (pmAC). However, soluble AC (sAC) provides another means of signaling 
that is not at the plasma membrane and might be more amenable to the intracellular 
localization of a GαS–coupled GPCR. G–proteins localized to organelle membranes 
[26,27] and signaling through sACs provides a basis for both specific, selective and 
discrete generation of cAMP in the cell [28–31]. A Kinase Anchoring Proteins (AKAPs) 
that localize PKA to the endomembrane of organelles (Figure 1.2) also provide  for 
activation of PKA in discrete compartments [32,33]. We hypothesized that subcellular 
targeting of cAMP or PKA reporters may provide information about compartment 
specific activation of TAAR1 GαS–AC–cAMP/PKA signaling in response to AMPH.  
RhoA is activated by family of guanine nucleotide exchange factors (GEFs) 
known as regulator of G–protein signaling (RGS)–homology domain (RH) containing 
guanine nucleotide exchange factors (RH–RhoGEFs) [34–36]. Current research suggests 
that RH–RhoGEFs are ubiquitous in the cytosol and provide a direct functional link 
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between Gα13 coupled GPCRs receptors and intracellular RhoA activation and signaling 
[34]. Following activation of  Gα13 coupled receptors or expression of constitutively 
active Gα13 G–proteins, RH–RhoGEFs translocate to the endomembrane surface where 
they interact with GTP–bound Gα13 G–proteins [34–39]. In this regard, it possible that 
activation of intracellular membrane bound Gα13 coupled TAAR1 receptors may facilitate 
localized activation of RhoA.  
Fӧrster (or Fluorescence) Resonance Energy Transfer (FRET)  
Fӧrster (or Fluorescence) resonance energy transfer (FRET) is a process in which 
non–radiative energy is transferred between donor and acceptor fluorophores, for 
example CFP and YFP (Figure 1.3A). FRET biosensors have contributed to our 
understanding of spatial and temporal dynamics of signaling molecules in live cells [40–
44]. An  intramolecular A–kinase Activity Reporter 4  (AKAR4) FRET biosensor was 
developed to examine real–time of PKA activity in single cells [41,42]. It has been 
further modified with the addition of targeting motifs to examine compartmentalization 
of PKA activation [42]. RhoA–based FRET biosensors have also been developed [43,45]. 
The general structure of both of these biosensors sandwiches a recognition sequence for 
PKA phosphorylation or activated RhoA between two fluorescent proteins with proper 
spectral overlap between donor emission and acceptor excitation [40,41,43]. In this study, 
we developed new targeted FRET sensors to monitor TAAR1–mediated 
compartmentalized PKA and RhoA activity in response to AMPH.  
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CHAPTER ONE: SPECIFIC AIMS 
 TAAR1 has been implicated in the pathophysiology of AMPH–related addiction 
and is necessary for maintenance of DA neuronal plasticity. As previously described, 
AMPH activation of TAAR1 regulates the trafficking of transporters whose functions are 
integral for proper dopaminergic neurotransmission in the mammalian brain. To better 
understand the role of TAAR1 in dopaminergic neurotransmission, we sought to examine 
the intracellular localization and functional compartmentalization of TAAR1 activation in 
vitro. Through the specific aims listed below for chapter one, we seek to address this gap.  
 The specific aims of chapter one are to:  
1) Identify organelle–targeting motif sequences.  
2) Design and characterize specific organelle–targeted PKA and RhoA FRET sensors.  
3) Test the ability of PKA and RhoA FRET sensors to respond to AMPH.  
4) Use a CRISPR–Cas9 knockout TAAR1 cell line to assess the role of TAAR1 in 
AMPH stimulated RhoA and PKA activation.  
A growing body of literature indicates that TAAR1 plays a role in several neuro–
addictive pathologies and is a promising candidate to target for treatment of these 
disorders [3,7]. The outcome of this study will allow us to further delineate the 
mechanism of action of AMPH on TAAR1 signaling and adds to our understanding of 
TAAR1 cell biology. Therefore, knowledge of intracellular membrane localization may 
assist us in evaluating and developing tools for pharmacotherapies targeting the TAAR1 
receptor.  
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MATERIALS & METHODS 
Materials 
Antibodies: Mouse monoclonal anti–α–Tubulin antibody was purchased from Sigma 
Aldrich (cat# T6074). Mouse anti–Golgin–97 primary antibody (cat# A–21270) was 
purchased from Invitrogen/ThermoFischer Scientific. Rabbit polyclonal anti–Green 
Fluorescent Protein (Anti–GFP) antibody was purchased from Marine Biological 
Laboratory (cat# 598). Mouse monoclonal GM130 (cat# ab31561), and rabbit anti–
VMAT2 (cat# ab191121) antibodies were purchased from Abcam. Rabbit anti–GAPDH 
(cat# G9545) and rabbit β–actin (cat# 4967L) antibodies were acquired from Sigma 
Aldrich and Cell Signaling respectively. The secondary antibodies donkey anti–mouse 
(cat# 715–035–150) horseradish peroxidase (HRP) and donkey anti–rabbit HRP (cat# 
31458) were acquired from Jackson Immuno Research Laboratories Inc and Pierce, 
respectively. 
 
Other reagents: dbcAMP, a cell permeable cyclic AMP analogue (cat# D026) was 
acquired from Sigma Aldrich. Reagents for SDS–PAGE, Bicinchoninic Bradford Protein 
Assay, LipofectamineTM 2000, Dulbecco's Modified Eagle’s Medium (DMEM), 
MitoTrackerRed CMXRos (cat# M7512), Fetal Bovine Serum (FBS) and all other culture 
media were purchased from Invitrogen/Life Technologies. cOmplete™, Mini, EDTA–
free Protease Inhibitor Cocktail (cat# 11836170001) was acquired from Roche 
Diagnostics. RhoA activator I (cat# CN01) and mitochondrial isolation kit (cat# 89874) 
were acquired from Cytoskeleton Inc and Pierce/Thermofischer Scientific, respectively. 
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All other reagents were purchased from Sigma Chemical Co. (St. Louis, MO) unless 
otherwise stated.  
 
Methods 
Targeted FRET sensors: pcDNA3.1(+)–AKAR4 was a gift from Jin Zhang (Addgene# 
61619) [41]. We designed two nuclear targeted AKAR4 reporters using the C–terminal 
nuclear localization sequence (NLS) of human cMYC proto–oncogene that codes for the 
amino acids PAAKRVKLDP or a C–terminal sequence of the SV40 Large T–antigen that 
codes for the amino acids PKKKRKVEDP. These targeting sequences were fused to the 
C–terminus of the AKAR4 plasmid followed by a stop codon before the EcoRV 
restriction site (Table I; Figure 1.3A). We observed that cMYC–AKAR4 exhibited less 
cytosolic fluorescence in comparison to SV40 AKAR4. Previous reports were that the 
cMYC–eGFP chimeras exhibited an increase in nuclear intensity by 160 % compared to 
that of the cytosol when compared to the eGFP–SV40 antigen NLS chimeras [46]. 
Therefore, all FRET experiments presented in this study were done with the cMYC–
AKAR4 (Nuclear–AKAR4) construct. Worthy of note, we did not target the AKAR4 
sensor to the outer membrane of the nucleus since it is contiguous with the ER 
membrane.  
Two Golgi targeting AKAR4 plasmids were designed using either the first 32 
amino acids from endothelial nitric oxide synthase (eNOSAKAR4) [47,48] or the C–
terminal amino acids of Golgi resident protein Giantin (GiantinAKAR4). The eNOS and 
Giantin targeting motifs were subcloned to the N–and C–terminus of the AKAR4 
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plasmid, respectively. The eNOSAKAR4 showed an increased amount of cytosolic 
expression compared to GiantinAKAR4 and did not colocalize with trans–Golgi marker 
Golgin–97 (See Appendix 1A). Therefore, in all experiments conducted in this study the 
GiantinAKAR4 construct was used and named Golgi–AKAR4. We also generated two 
mitochondrial PKA sensors using a motif derived from N–terminal amino acids (1–30) of 
the mitochondrial A–kinase anchoring protein 1 (D–AKAP1) or the first thirty–three 
amino acids of Tom20, an outer–membrane mitochondrial (OMM) protein. Both sensors 
directed the AKAR4 reporter to cytosolic face of mitochondria [41,49–51]. For the 
experiments described in this study, the Tom20 targeted AKAR4 was used (Mito–
AKAR4). The mitochondrial targeting motifs were fused to the N–terminus of the 
AKAR4 sensor between the HindIII and BamHI sites (Figure 1.3A).  
The synaptic vesicle (SV) targeted AKAR4 reporter was generated by subcloning 
a forty–four amino acid localization motif from the vesicular monoamine transporter 2 
(VMAT2) to the C–terminus of the AKAR4 plasmid. All reporters generated were 
sequenced verified using the following primers: Forward 5’–
CCACTTTGAATTTCTCTCCAC–3’ and Reverse 5’–
ATTTGTGATGCTATTGCTTTATTTGTAACC–3’ (Macrogen USA, Rockville, MD). 
The lipid–raft membrane reporter(Lyn–AKAR4) and the non–lipid raft membrane 
reporter (Kras–AKAR4) plasmids were gifts from Jin Zhang (Addgene# 61620 and 
#61621, respectively) [42].  
An enhanced RhoA FRET sensor (RhoA–2) was a gift from Dr. Mark Rizzo. The 
Rizzo lab replaced the enhanced cyan florescent protein (eCFP) with the brighter third 
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generation fluorophore mCerulean3 [52]. A schematic of the plasmid map is shown in 
Figure 1.12A. To target the RhoA–2 biosensors to the mitochondria, the N–terminal 
localization motif from Tom20, was used and fused to the N–terminus of the RhoA–2 
plasmid between the Pac I and NcoI restriction sites (Table I; Figure 1.11A). For the 
GolgiRhoA–2 plasmids, the C–terminal localization motif of Giantin was used. The 
synaptic vesicle (SV) targeting RhoA was also generated using the cytoplasmic C–
terminal localization motif of VMAT2 and was fused to the C–terminus of the enhanced 
RhoA–2 FRET sensor. The ER targeting sensor was generated by Dr. Underhill in the 
Amara lab by fusing the N–terminal localization motif of cytochrome p450 to the RhoA–
2 plasmid. All C–terminal localization motifs were subcloned into the C–terminus of the 
RhoA–2 plasmid following a stop codon before the XhoI site (Figure 1.12). All final 
targeted RhoA–2 plasmids were sequenced verified using the following primers: Forward 
5’–GAGGTTTTTGAAATGGCTACGAG–3’ and Reverse 5’–
CAGGCTGCCAGCAGCTTGCAGGC–3’ (Macrogen USA, Rockville, MD). 
  
Cell Culture and Transfection: SK–N–SH and HEK293 cells were obtained from 
American Type Culture Collection (ATCC, Rockville, MD, U.S.A.) while TAAR1 
knockout SK–N–SH cell line was generated by Dr. Jingshan Chen in the Amara lab (See 
details below). All cells were maintained in DMEM supplemented with 0.1 % 
Penicillin/Streptomycin and   5 % FBS at 37 oC in a humidified incubator containing 5 % 
CO2. All cells were transfected using Lipofectamine™ 2000 according to the 
manufacturer’s protocol, with slight modifications. In brief, plasmid DNA (1 μg) and 
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Lipofectamine™ 2000 (3 μL) were incubated in 50 μL of Opti–MEM (Life 
Technologies) separately for 5 minutes. The solutions were then combined and incubated 
at room temperature (RT) for 20 minutes. 20 ×106 cells were added to the solution and 
incubated for 1 h at room temperature (RT) before plating onto poly–D–lysine coated 
plates or glass coverslips. Imaging, fractionation, western blot analysis, drug treatments 
and immunocytochemistry were carried out between 24 to 48 h post transfection. All cell 
culture assays were performed on cultures from at least three different plating procedures 
creating at least three biological replicates. Where possible, experiments were performed 
under blinded conditions. 
Knock Out Cell Line: Dr. Jingshan Chen in the Amara lab used CRISPR–Cas9 
technology to generate the TAAR1 knockout SK–N–SH cell line. In brief, guide RNA 
primers that target 20–27 codons of the TAAR1 genomic DNA were designed and 
introduced into the SK–N–SH cells via transfection along with CRISPR associated 
protein 9 (Cas9) DNA endonuclease (See Appendix 2A). The Cas9–mediated double 
stranded breaks were repaired by non–homologous end joining and resulted in deletion of 
less than three nucleotides causing a frameshift that generated premature stop codons 
resulting in the expression of truncated, nonfunctional TAAR1 proteins (See Appendix 
2A).  
 
Immunohistochemistry: Cells were fixed in 4 % paraformaldehyde (PFA) at RT for 15 
minutes.  After three washes with phosphate–buffered saline (PBS), cells were 
permeabilized with 0.20 % Triton X–100 for 5 minutes and blocked with 5 % normal 
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goat serum (NGS) for 1 h at RT before incubation with primary antibodies diluted in 5 % 
NGS overnight at 4 °C on a shaker. Primary antibodies were washed away with PBS and 
secondary antibodies applied in 5 % NGS for 2 h at RT. Secondary antibodies were 
washed off, and the coverslips were mounted in FluoromountTM Aqueous Mounting 
Medium (cat# F4680; Sigma Aldrich) for subsequent examination.  
 
MitoTracker Labelling: Twenty–four hours post transfection, the mitochondria were 
identified by staining with MitoTrackerRed CMXRos, a mitochondria specific 
fluorescent dye. In these experiments, MitoTrackerRed CMXRos was added to the cells 
at a final concentration of 25 nM for 15 minutes at 37 oC. The cells were then washed 
five times with warm culture media and incubated under normal culture conditions for 30 
minutes prior to live cell imaging. The cells were then washed with PBS and imaged as 
described below. 
 
Mitochondrial Isolation: To confirm the proper localization of the mitochondrial 
targeting biosensors generated, we isolated mitochondrial fractions from SK–N–SH and 
HEK293 cells transfected with the mitochondrial targeting plasmids using a 
Mitochondria Isolation Kit for cultured cells according to the manufacturer’s protocol. In 
brief, crude mitochondrial fractions from cells transfected with mitochondrial targeted 
sensors were isolated in a proprietary buffer at 12, 000 × g and analyzed by 
immunoblotting. Purity of the mitochondrial fraction was assessed by the presence of 
Tom20 (a mitochondrial marker) and absence of α–tubulin (a cytosolic marker).  
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ER/Golgi Microsome Isolation: HEK293 cells were transfected with either GolgiRhoA–2 
or Golgi–AKAR4 plasmids and plated in T75 cm2 flasks. Twenty−four hours after 
transfection, the cells were detached with trypsin, pelleted at 600 × g for 5 minutes and 
washed with PBS. The pellet was subsequently used for isolation of ER/Golgi 
microsomal fractions using a commercially available kit (Sigma Aldrich, cat# ER0100). 
In brief, the cell pellet was resuspended in a hypotonic homogenization buffer containing 
protease inhibitor cocktail, allowed to swell for twenty minutes at 4 oC and then pelleted. 
The cells were resuspended in isotonic buffer containing protease inhibitor and lysed 
using a Dounce homogenizer. Unlysed cells and nuclear debris were separated by 
centrifugation at 1,000 × g for 10 minutes. The supernatant from this step was further 
centrifuged at 12,000 × g for 10 minutes to pellet the mitochondria. The post 
mitochondrial supernatant was used for precipitation of ER/Golgi microsome fraction 
with 8 mM calcium chloride, which was added dropwise with constant agitation at 4 oC. 
The ER/Golgi microsome fraction was pelleted by centrifugation at 8,000 × g for 10 
minutes at 4 oC. The pellet was dissolved in a RIPA lysis buffer containing 100 mM 
Tris−HCL pH 7.4; 300 mM NaCl; 2 % NP−40; 1 % sodium deoxycholate and 0.2 % 
sodium dodecyl sulfate (RPI Research, USA). Enrichment of the ER/Golgi microsome 
fraction was confirmed by the presence of GM130 Golgi marker and absence of β−actin 
(a cytosolic marker) as well as GAPDH (a cytoplasmic marker).  
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Immunoblot: Immunoblotting was performed as described previously, with slight 
modifications [21]. Briefly, cells were homogenized in lysis buffer containing 50 mM 
Tris–HCl, pH 7.5, 150 mM NaCl, 5 mM EDTA, 1 % Triton X–100, 4 mM N–
ethylmaleimide and protease inhibitor. Lysates were centrifuged at 20,000 × g for 10 
minutes at 4 oC and the supernatant fraction was used for western blots. All primary 
antibodies used in these experiments were used at a concentration of 1:1000 unless 
otherwise indicated. Following overnight incubation with primary antibodies at 4 oC, 
each blot was probed with the appropriate HRP–conjugated secondary antibody (1:5000) 
for 1 h at RT. Immunoreactive signals were visualized using Western Lightning™Plus–
ECL Enhanced Chemiluminescence Substrate (Perkin Elmer, cat# NEL104001EA) and 
detected with a chemiluminescence imaging system (Bio–Rad Laboratories).  
 
Live Cell Imaging and Data Analysis: Cells were washed twice with warm phenol red 
deficient DMEM then imaged at RT for 30–60 minutes. Cells were treated with drugs as 
indicated after two or five minutes of baseline FRET acquisition. Images were acquired 
on a Nikon AR1 equipped with a 60X/1.3 NA oil–immersion objective lens and NIS 
Elements Advanced Research software. Dual emission ratio imaging was performed 
using a 457 nm excitation filter, and two emission filters (440 nm for CFP and 617.5 nm 
for YFP). Images were acquired every 10 seconds. Background correction of fluorescent 
images was performed by subtracting the intensities of regions of the imaging field where 
fluorescence was absent (Formula 1). 
             𝐹𝑅𝐸𝑇𝑟𝑎𝑡𝑖𝑜 =  
(𝐴𝑐𝑐𝑒𝑝𝑡𝑜𝑟 𝑌𝐹𝑃−𝐴𝑐𝑐𝑒𝑝𝑡𝑜𝑟 𝑌𝐹𝑃𝐵𝑘𝐺𝑟𝑑)
(𝐷𝑜𝑛𝑜𝑟 𝐶𝐹𝑃−𝐷𝑜𝑛𝑜𝑟 𝐶𝐹𝑃𝐵𝑘𝐺𝑟𝑑)
=  
𝑌𝐹𝑃
𝐶𝐹𝑃
                              Formula 1 
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The YFP/CFP ratios at each time point were normalized to the two–minute baseline 
levels preceding drug application (Formula 2).  
                 𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 𝐹𝑅𝐸𝑇 =  
(𝐹𝑅𝐸𝑇 𝑟𝑎𝑡𝑖𝑜𝑇𝑖𝑚𝑒 (𝑡))
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 
𝑌𝐹𝑃
𝐶𝐹𝑃𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒
× 100%                              Formula 2  
The FRET ratios at given time (t) calculated using Formula 1 were normalized by 
dividing by the FRET ratios at baseline (2 minutes prior to drug treatment). Graphs of the 
ratio time course (ratio vs time) were plotted, and statistical analysis was performed with 
GraphPad Prism version 6.0 (GraphPad Software, La Jolla, CA). Selection criteria for 
each cell was as follows: (1) those that were saturated in either the CFP or YFP 
wavelength at the start of the experiment were removed from analysis; (2) cells that did 
not respond to subsequent treatment with dbcAMP or Rho Activator I  were discounted; 
(3) and, for HEK293 cells, we excluded cells that responded to the classic activators but 
not to AMPH suggesting that these cells do not co–express the DAT transporter required 
for AMPH entry into the cell within the time frame of the experiment.  
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RESULTS 
Design and localization of targeted PKA biosensors 
To understand how and where TAAR1 elicits PKA activity in the cell, we 
targeted the A–Kinase Activity Reporter 4 (AKAR4) PKA biosensor to the Golgi, 
mitochondria, synaptic vesicles and nucleus using different targeting motifs (Table I). 
The membrane targeted motifs anchor the sensor to the cytoplasmic facing membrane of 
the organelle, allowing for activation by PKA [42]. The nuclear localization signal 
localized the nuclear reporter inside the nucleus. The Mito–AKAR4 reporter was found at 
the cytoplasmic face of the outer–membrane of the mitochondria of HEK293 (Figure 
1.4A) and, SK–N–SH cells (Figure 1.4A) as evidenced by confocal microscopy. We 
further validated the specific localization of Mito–AKAR4 in HEK293 cells using a 
reagent–based mitochondrial isolation kit followed by immunoblotting analysis (Figure 
1.4B). Probing the cytosolic and mitochondrial fractions for the green fluorescent protein 
(GFP) to identify the FRET sensor, Tom20 (a mitochondrial marker) and α–Tubulin (a 
cytosolic marker) demonstrated that Mito–AKAR4 predominantly enriched in the 
mitochondrial fractions. The untargeted donor AKAR4 plasmid was found in the 
cytosolic fraction (Figure 1.4B; Appendix 3A). Colocalization with mitochondrial 
marker, MitoTracker confirmed this finding (Figure 1.4C). 
 The Golgi–AKAR4 sensor did not appear to alter the structure of the Golgi upon 
overexpression (Figure 1.5A) and colocalized with the cis–Golgi marker GM130 (Figure 
1.5A). Additionally, subcellular fractionation of the ER/Golgi membranes demonstrated 
that Golgi–AKAR4 was properly localized in the GM130 positive fraction of Golgi 
 18 
(Figure 1.5B). The purity of the Golgi/ER microsomes was verified by the presence of 
GM130 and the absence of GAPDH and β–actin (Figure 1.5B).  
The nuclear localization signal (NLS), PAAKRVKLD, derived from human c–
Myc protooncogene protein (Table I), was fused to the C–terminus of AKAR4 to target 
PKA biosensors to the nucleus [46]. Nuclear AKAR4 colocalized with DAPI a DNA 
stain that indicates the nucleus (Figure 1.6).  
Szumska and colleagues reported that TAAR1 in thyrocytes was localized to 
vesicles of the secretory pathway [12]. We hypothesized that in neurons, this might be 
analogous to synaptic vesicles, so we also generated a AKAR4 sensor targeted to 
synaptic vesicles (SV–AKAR4; Table I) using  a synaptic vesicle trafficking motif 
derived from VMAT2 [53,54]. Proper targeting of SV–AKAR4 was verified in SK–N–
SH cells, which express synaptic vesicles and endogenous VMAT2 (Figure 1.7A).  While 
the expression of the SV–AKAR4 biosensor was visually analogous to VMAT2 positive 
synaptic vesicles (Figure 1.7A, B), at this time, confirmation of this is hampered by the 
lack of a viable antibody for synaptic proteins like synapsin I and synaptotagmin I.  
 
Organelle–specific intramolecular PKA biosensors are stimulated by cAMP  
Baseline FRET emissions for all PKA biosensors were stable (Figure 1.8A). The 
functional activity of the targeted PKA sensors was assessed in HEK293 and SK–N–SH 
cells by stimulation with a membrane permeable analogue of cAMP, dibutyrl cAMP 
(dbcAMP, 1mM). HEK293 or SK–N–SH cells expressing the targeted AKAR4 sensors 
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were stimulated with dbcAMP and an increase in FRET emission was observed 
indicating functional reporters (Figure 1.8B).  
 
PKA activation in response to AMPH is most robust near the synaptic vesicles 
 To activate TAAR1, AMPH must enter the neuron through the dopamine 
transporter (DAT) [17,49]. We co–transfected the Mito–AKAR4 biosensor with or 
without DAT in HEK293 cells to determine if PKA activation of the targeted AKAR4 
reporter was also depended upon DAT co–expression and presumably, AMPH entry into 
the cell.  In cells that did not express DAT, we did not observe a significant increase in 
Mito–AKAR4 FRET activity in response to AMPH (10 µM) (Figures 1.9A–C), 
confirming previous data suggesting that DAT is required for AMPH activation of 
TAAR1. After twenty minutes, there is a slight increase in PKA activation in cells 
without DAT (Figures 1.9A and C), which was also observed in cells treated with vehicle 
controls (data not shown) indicating that it reflects non–specific baseline activity. The 
change in FRET emission normalized to a five–minute baseline was found to be 117.45 ± 
1.73 % at thirty minutes for cells transfected with both DAT and Mito–AKAR4 compared 
to the 103.95 ± 0.85 % in cells that were not co–transfected with DAT (Figure 1.9A). 
Statistical analysis of the area under the curves (AUC) demonstrates significant AMPH–
mediated PKA activation in the presence of DAT (Figure 1.9B; **** p < 0.0001). 
Representative images of the change in FRET YFP/CFP ratios in the presence or absence 
of DAT at various time points are shown in Figure 1.9C. 
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To ensure that all plasmids were equally co–transfected with DAT and the 
AKAR4 construct of interest, we assessed protein expression with western blots. No 
difference in co–expression was observed among the plasmids (data not shown). The 
organelle–targeted PKA–FRET based sensors enabled us to assess PKA responses to 
AMPH in different subcellular compartments including the Golgi, mitochondria, lipid–
raft, non–lipid raft, nucleus and synaptic vesicle compartments (Figures 1.10 and 1.11). 
The most robust activation of PKA by AMPH in SK–N–SH cells occurred when the 
sensor was targeted to synaptic vesicles (Figure 1.11C). Maximum FRET–emission ratio 
for the SV–AKAR4 plasmid at thirty minutes was 158.5 ± 8.3 % (n=36), compared to 
112.1 ± 1.2 % (n=18) for Golgi–AKAR4; 112.26 ± 1.7 % (n=24) for Lyn–AKAR4; 111.6 
± 1.9 %  (n= 30) for Mito–AKAR4; 110.0 ± 1.2 % (n=14) for Kras–AKAR4 and 111 ± 
0.7 % (n=34) for Nuclear–AKAR4. In HEK293 cells there was no significant difference 
in responses of the AKAR4 targeted FRET sensors; however, HEK293 cells do not 
possess synaptic vesicles that may preclude proper function/localization in this model 
system.   
 
Design and characterization of organelle–targeted RhoA–2 FRET biosensors 
 An enhanced RhoA sensor was developed for this study by replacing enhanced 
CFP (eCFP) with mCerulean3 (Figure 1.12A) [52]. Underhill et al. showed that the 
addition of the brighter CFP mCerulean3 increased the FRET emission activity 
(unpublished). Using the targeting motifs in Table I, we designed and characterized the 
targeted RhoA reporters. The proper targeting of RhoA–2 sensors was confirmed as 
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described above for the respective AKAR4 sensors. MitoRhoA–2 colocalized with 
MitoTracker (Figure 1.13A) and was enriched in crude mitochondrial fractions (Figure 
1.13B). The GolgiRhoA–2 sensor co–localized with the cis–Golgi marker GM130 
(Figure 1.14A) and did not distort normal morphology of the Golgi apparatus. Isolation 
of Golgi microsomes followed by western blot analysis further demonstrated that the 
targeted GolgiRhoA–2 sensors were enriched in these fractions indicating proper 
targeting of the sensors (Figure 1.14B). 
We also generated RhoA sensors targeted to synaptic vesicle (SVRhoA–2) 
membrane and the nucleus (NuclearRhoA–2). The NuclearRhoA–2 sensor colocalizes 
with DAPI in transiently transfected SK–N–SH cells (Figure 1.15A). The expression 
pattern of the targeted SVRhoA–2 sensor in SK–N–SH cells (Figure 1.15B) is 
reminiscent of classic synaptic vesicle puncta [55].  
RhoA activation in response to AMPH favors the ER and Golgi compartments  
The targeted RhoA–2 FRET sensors enabled us to assess RhoA activation to 
AMPH in different subcellular compartments including in the Golgi, mitochondria, ER, 
nucleus and synaptic vesicle compartments in HEK293 (Figure 1.16A) and SK–N–SH 
neuroblastoma cells (Figure 1.17A). Baseline FRET emissions for all RhoA sensors were 
stable (Figure 1.16B). In SK–N–SH (Figure 1.16B, C) and HEK293 cells (Figure 1.15C, 
D), the FRET sensors exhibited preferential AMPH mediated RhoA activation at the 
Golgi, and ER membranes compared to mitochondrial, nuclear and synaptic vesicle 
sensors.  
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RhoA activation in TAAR1 Knockout (KO) Cells 
Previous studies using the untargeted RhoA–2 sensor in wildtype SK–N–SH and 
TAAR1 KO cell lines have indicated that AMPH–induced RhoA activation is dependent 
upon TAAR1 activation (unpublished). Similarly, in SK–N–SH cells lacking TAAR1, 
AMPH stimulation of RhoA is attenuated in almost all organelle compartments (Figure 
1.18A; B7). In the absence of TAAR1, AMPH–induced RhoA activation is significantly 
reduced in the Golgi, ER, nuclear and synaptic vesicle compartments; however, there is 
no significant difference in RhoA activation in the mitochondrial compartment (Figure 
1.18B). These data suggest that the functional site of Gα13 coupled TAAR1 receptors is 
localized near the perinuclear membrane compartments of the ER, Golgi.  
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DISCUSSION 
The subcellular localization of TAAR1 determines its availability for its ligands 
including amphetamine (AMPH) [12,56]. The data presented here provides evidence that 
TAAR1–mediated PKA and RhoA activation in response to AMPH occurs in distinct 
compartments of the SK–N–SH neuroblastoma cell line. AMPH entry into the cell 
requires the DAT [19]. In the cell, AMPH activates TAAR1, which leads to increased 
PKA and RhoA signaling. Unpublished data from the Amara lab suggests that TAAR1–
dependent activation of PKA and RhoA is accomplished through activation of Gαs and 
Gα13 coupled TAAR1 receptors, respectively. Elevated RhoA and PKA signaling in 
response AMPH reciprocally regulate the internalization of DAT and EAAT3 
transporters and requires TAAR1 [19]; RhoA activation enhances transporter 
internalization, whereas PKA signaling decreases RhoA activation and inhibits 
internalization. In the brain, TAAR1 is co–expressed with DAT and EAAT3 in a subset 
of DA neurons in the VTA and SN—areas in the brain that have been implicated in drug 
addiction. DAT and EAAT3 function to regulate synaptic neurotransmitter levels. 
Therefore, TAAR1–dependent effects of AMPH on DAT and EAAT3 demonstrate that 
TAAR1 modulates monoaminergic activity in the brain.  
The observation of TAAR1’s intracellular localization compelled researchers to 
seek to and identify the membrane localization of TAAR1. Due to limitations of 
immunolabeling and inconclusive overexpression studies with TAAR1 and its chimeras, 
the subcellular and functional localization of TAAR1 has not been demonstrated in a 
neuron. To address this issue, we hypothesized that the use of PKA and RhoA–based 
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FRET reporters might help to delineate the subcellular and functional localization of 
TAAR1 using AMPH as a ligand.    
Selectively targeted PKA and RhoA–based FRET sensors using organelle–
specific targeting motifs were designed and characterized. The Mito–AKAR4 and 
MitoRhoA–2 sensors localized to the cytoplasmic face of the mitochondria as evidenced 
by peripheral colocalization with MitoTracker, indicating that the mitochondrial reporters 
are accessible for activation by PKA and/or RhoA guanine nucleotide exchange factors. 
The activation of Mito–AKAR4 by dbcAMP a cAMP analog that activates cAMP–
dependent protein kinases, is consistent with other previously reported mitochondrial 
targeted PKA sensors [41].  Golgi–AKAR4 and GolgiRhoA–2 targeted sensors, 
colocalized with the cis–Golgi marker GM130. Nuclear and synaptic vesicle targeted 
PKA and RhoA reporters were all functional as indicated by increased FRET emission in 
response to pharmacological activators. Note, that the nuclear reporter was not targeted to 
the nuclear outer membrane because it is contiguous with the ER membrane. The activity 
of the lipid–raft and non–membrane raft targeting AKAR4 sensors and the ERRhoA–2 
sensor previously developed and characterized by the Zhang and Amara laboratories, 
respectively were consistent with previously reported findings.  
Our results suggest that we can use targeted sensors to identify the subcellular 
regions where AMPH activates PKA and RhoA pathways and begin to address the 
compartment(s) where TAAR1 signaling occurs. In SK–N–SH cells, PKA activation 
significantly favors the synaptic vesicle compartment, however, in HEK293 cells the 
increase PKA activity in response to AMPH has a broader more diffuse distribution 
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within the cell. Together with the results of previous studies, these findings suggest that 
the dynamic localization of PKA and other upstream signaling molecules in this pathway, 
perhaps through mechanisms involving AKAP proteins, allows for compartmentalization 
of cellular activities. The absence of synaptic vesicles in HEK293 cells may account for 
the absence of differential SV–AKAR4 activation in these cells.  However, SK–N–SH 
cells express VMAT2 and small synaptic vesicles reminiscent of neuronal synaptic 
vesicle. The robust level of TAAR1–mediated PKA signaling in response AMPH near 
synaptic vesicles is supported by evidence from several labs suggesting that TAAR1 can 
regulate monoamine uptake through DAT in striatal synaptosomes and the VTA 
[10,13,14]. For example, ectopic expression TAAR1 has been shown to increase the 
extracellular levels of neurotransmitter DA, and NE in the NAc and of serotonin in the 
medial PFC as evidenced by spontaneous firing rate of monoaminergic neurons in the 
VTA, dorsal raphe nucleus, and locus coeruleus [10]. However, TAAR1 regulation of 
vesicular transport and storage has not been demonstrated. Consistent with our results 
suggesting that TAAR1 maybe be localized in or near synaptic vesicles, immunolabelling 
studies in thyroid tissue show that secretory vesicles in thyrocytes are immunopositive for 
TAAR1 [12]. Further studies using TAAR1 KO cells will be needed to confirm TAAR1 
localization to the synaptic vesicle compartment in the neuron. 
Evidence for TAAR1 localization to the ER and Golgi is also consistent with 
immunolabelling studies in thyrocytes [12]. Consistent with this, TAAR1–mediated 
RhoA signaling in response to AMPH is favors the endoplasmic reticulum (ER) and 
Golgi compartments of SK–N–SH and HEK293 cells. This conclusion is based on 
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several lines of evidence. First, AMPH treatment in cells transfected with the Golgi and 
ERRhoA–2 sensors led to a robust and significant increase RhoA–2 FRET emission 
compared to all other compartments (Figure 1.17 B–C). In the absence of TAAR1, RhoA 
activation by AMPH was significantly attenuated in the Golgi and ER compartments 
(Figure 1.18B). This signal was not completely abolished (Figure 1.18B) suggesting one 
of two possibilities: 1) TAAR1 may not be the only receptor mediating AMPH–induced 
RhoA activation and signaling or 2) a certain RhoA baseline activity is relevant even in 
the TAAR1 KO cell line. Worthy of note, the latter may explain why there was no 
observed difference in RhoA FRET activity in the mitochondrial compartment between 
the cell lines (Figure 1.18B). To resolve this full vehicle controls should be used.  
The ability of the TAAR1 receptor to couple to different signaling pathways that 
display distinct spatial and temporal properties is supported by the fact that the 
downstream components of these pathway are also distinct and can differ in their 
distribution and kinetics [24]. Taking together, differential PKA response at the synaptic 
vesicles along with preferential RhoA activation in the Golgi and ER components further 
confirm that there may be two pools of TAAR1 receptors (unpublished). Our data 
suggests that GαS coupled TAAR1 receptors maybe positioned near the synaptic vesicles 
where they may mediate monoamine storage and release and Gα13 coupled TAAR1 
receptors are localized near the ER/Golgi compartments.  
Future studies will seek to further expand our understanding of the downstream 
effects of AMPH on TAAR1 signaling and defining the membrane localization of 
TAAR1 in neurons. Commonly used methods such as, subcellular fractionation of 
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subcellular membrane compartments could provide a static glimpse of TAAR1 
trafficking. Developing a TAAR1 antibody for western blot analysis of isolated ER, 
Golgi and synaptic vesicle membranes fractions may allow us to confirm that TAAR1 is 
differentially localized to these membrane compartments. Additionally, we can also 
address whether Gα13  proteins colocalize with TAAR1 at the ER and Golgi membranes 
by immunolabelling.   
To delineate the functional significance of increased GαS PKA signaling in the 
synaptic vesicle compartment we will further characterize the SV–AKAR4 sensor using, 
immunolabelling and sucrose gradient centrifugation, and explore the possible role of 
TAAR1 activation in vesicular transport (See Chapter II). As GαS–cAMP–PKA signaling 
is highly dynamic, we may need to employ other sensors upstream of the activated 
protein kinase A–AKAP interaction. Calcium and cAMP may both be required for PKA 
activation [29] and the use of a cAMP and calcium sensors may assist us in further 
characterizing the signaling compartment used by TAAR1. Dual FRET imaging could be 
used to assess AMPH evoked changes in calcium and PKA activity, as used by Dunn et 
al. to determine the specific roles of  various ACs and PDEs in calcium–dependent 
activation of the cAMP/PKA signaling [29]. A more holistic view of these signaling 
cascades may be explored with targeted sensors to other cellular compartments including 
the lysosome, peroxisome and endosome.  
In summary, we have designed and characterized new subcellular compartment 
targeted FRET sensors for use in identifying the functional site of TAAR1–mediated 
PKA and RhoA activation in response to AMPH. This method provides a means to 
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explore how coupling of intracellular TAAR1 to different G–protein subunits results in 
different spatial and temporal patterns of downstream signaling. Using these sensors, we 
found that Gα13 coupled TAAR1 receptors responsible for AMPH induced RhoA 
activation display most robust activation of RhoA with sensors targeted to ER/Golgi 
compartments while the GαS coupled TAAR1 receptors responsible for PKA activation 
appear to generate signals that more prominent in or near the synaptic vesicle membrane. 
Better antibodies specific for identification of TAAR1 in the neuron are required to 
establish the precise membrane distribution of TAAR1. As TAAR1’s location in the cell 
determines its availability to ligands including AMPH and METH it is necessary that we 
determine TAAR1’s membrane localization [56]. As new tools to study TAAR1 are 
developed we can look forward to expanding our understanding of the physiological 
effects of AMPH on TAAR1 signaling towards delineating the dynamic localization and 
pharmacokinetic properties of TAAR1 in both therapeutic and addictive actions of 
psychostimulant drugs [24].    
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Figure 1.1| TAAR1 structure and ligands. (A) Predicted model of the transmembrane 
topology of the human trace amine associated transporter 1 (hTAAR1). TAAR1 is a 
seven transmembrane (TM) G–protein coupled receptor. The gray shaded amino acid 
residues in the TM domains are phylogenically conserved. Putative N–terminal 
glycosylation sites at asparagine residues N10 and N17 should confer localization to the 
plasma membrane; however, TAAR1 is predominantly localized intracellularly and the 
N–terminal glycosylation sites may govern activity dependent TAAR1 membrane 
localization [57,58]. Image was adapted from Lindemann et al. 2008 [9]. (B) Trace 
amines share similar structural, and metabolic pathways as the neurotransmitter 
dopamine. The enzyme aromatic–L–amino acid decarboxylase (AADC) is necessary for 
the conversion of aromatic amino–acids to biogenic amines like DA and for generating 
endogenous trace amines (TAs). The most potent trace amine, ρ–tyramine is formed from 
the tyrosine substrates, while β–PEA is formed from phenylalanine. The absence of MAO 
increases the half–life and account for physiological effects of TAs seen in patients with 
tyramine storm [3,5,6,59].  
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Figure 1.2| Subcellular targeting of PKA signaling through AKAPs. AKAPs target 
PKA, along with its substrates and regulators to form a complex at specific organelle 
compartments, for example, mitochondria, Golgi, and nucleus. The binding of AKAPs to 
specific partners, such as phosphodiesterase (PDE) regulates the activation and 
deactivation of PKA signaling. Activation of GαS coupled GPCRs turns on soluble and/or 
plasma membrane bound adenylyl cyclases (sACs; pmACs) resulting in elevated 
formation of intracellular cAMP from ATP. Four cAMPs then bind to regulatory subunits 
of PKA leading to the activation of PKA. PDE locally promote rapid inactivation of 
cAMP to AMP and dephosphorylation of PKA substrates. AKAP350 (Golgi), D–AKAP1 
(mitochondria), and AKAP95 (nucleus) tethers PKA and compartment specific PDE and 
AC which together act to maintain cAMP homeostasis in each microdomain of the cell 
[32]. This image was modified from Asirvatham et al. 2004 [32]. 
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Figure 1.3| A–Kinase Activity Reporter 4 (AKAR4) FRET biosensor. (A) Schematic 
of AKAR4, a PKA–based Intramolecular FRET reporter. The AKAR4 plasmid construct 
of the intramolecular PKA biosensor consists of the phosphoamino–acid–binding domain 
of the forkhead associated protein 1 (FHA1, purple), which selectively binds to the 
phosphorylated PKA substrate (LRRATLVD, green).  In the target PKA substrate motif 
sequence, the characters labelled in green and purple indicate the residues for 
phosphorylation, and FHA1 binding respectively. The phosphate binding domain is 
separated from the donor cyan fluorescent protein, mCerulean (CFP, blue) by a glycine 
linker. Another glycine linker separates the yellow fluorescent protein variant, cpVenus 
(YFP) from the PKA substrate [41,42]. The PKA substrate is separated from cpVenus by 
another glycine linker. The organelle targeting sequence motifs were added to the N–or 
C–terminal of the AKAR4 plasmid using the restriction sites indicated. Schematic was 
adapted from Depry et al. 2011 [42]. (B) Mechanism of Intramolecular PKA–FRET. 
Phosphorylation of the surrogate PKA substrate by PKA promotes the association of the 
FHA1 domain to the substrate, inducing a conformational change, which brings the donor 
CFP and YFP closer together resulting in an increased FRET emission. The diagram in B 
was adapted from Komatsu et al. 2011 [43].   
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Table I| Targeting motifs. The targeting motifs were fused to the AKAR4 and RhoA–2 
FRET–based reporters. The nontargeted AKAR4 plasmid was obtained as a gift from 
Zhang laboratory [42]. The asterisk (*) indicates that these plasmids with these targeting 
motifs were designed and generated prior to this study. The targeting motifs of Lyn, Kras 
and ER were added to AKAR4 by the Zhang laboratory and were also acquired as gifts 
[42,60]. These three motifs were also added to the RhoA–2 FRET sensor prior to this 
study by the Amara lab (unpublished). 
 
 
 
 
 
 
 33 
 
 
Figure 1.4| Mitochondrial targeting of AKAR4. (A) Confocal images of Mito–AKAR4 
in HEK293 and SK–N–SH cells. Mito–AKAR4 (green) and DAPI (nucleus, blue) in 
HEK293 and SK–N–SH cells. Scale bar, 10 μm. (B) Mito–AKAR4 is targeted to 
mitochondrial fractions. HEK293 cells were transfected with Mito–AKAR4 or the non–
targeted AKAR4 construct. Mitochondrial fractions were isolated with a mitochondrial 
isolation kit. Following isolation, the samples were analyzed by western blot for GFP, 
Tom20 (a mitochondrial marker) and α–tubulin (a cytosolic marker). Non–transfected 
HEK293 cells were processed in parallel as a negative control. Mito–AKAR4 localizes 
predominantly to the mitochondrial fraction, M while AKAR4 is found in the 
cytoplasmic fraction, C. (C) Live cell imaging of Mito–AKAR4 and MitoTracker. Mito–
AKAR4 (green) colocalized with MitoTracker (red) and appears at the peripheral and 
outer membrane of the mitochondria in SK–N–SH cells. Yellow in merge shows 
colocalization. Scale bar, 10 μm. 
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Figure 1.5| Localization of Golgi–AKAR4. (A) Golgi–AKAR4 colocalizes with cis–
Golgi marker GM130. SK–N–SH cells were transiently transfected with Golgi–AKAR4 
(green) and probed with a GM130 antibody (red). Scale Bar, 10 µm. (B) Golgi–AKAR4 is 
enriched in Golgi microsomes. Crude microsomal preparations of the Golgi followed by 
western blot analysis for GFP further confirms Golgi–AKAR4 localization. GM130 (a 
Golgi Marker), β–actin (a cytosolic marker) and GAPDH (cytosolic markers) were used 
as controls for the Golgi and cytosolic fractions. 
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Figure 1.6| Characterization of the Nuclear–AKAR4 biosensor. Nuclear–AKAR4 
(green) colocalized with DAPI (blue). Scale bar, 10 μm. 
 
 
 36 
 
 
Figure 1.7| Cellular distribution of  SV–AKAR4. (A) SK–N–SH cells express VMAT2.  
SK–N–SH cells were stained with antibodies to the vesicular monoamine transporter 2, 
VMAT2 (red) and a DNA marker DAPI (blue) stains the nucleus. VMAT2 positive 
staining appears as punctate dots through the cell. Scale bar, 10 μm. (B) SV–AKAR4 
expression profile resembles synaptic vesicle and VMAT2. SK–N–SH cells transfected 
with SV–AKAR4 show that the sensor has a punctate (white arrow) distribution in the 
cell similar to VMAT2 positive synaptic vesicles. Scale bar, 10 μm.  
 
 
 37 
 
 
Figure 1.8| Organelle–specific intramolecular PKA biosensors are stimulated by 
cAMP.  (A) Basal PKA activation was steady prior to administration of cAMP analogue 
dbcAMP. Baseline recording of PKA reporters prior to pharmacological activation by 
dbcAMP indicate steady state activation of PKA at 100 %. (B) dbcAMP activates targeted 
AKAR4 sensors. Treatment of SK–N–SH cells expressing the respective AKAR4s led to an 
increase in FRET emission ratios for all AKAR4 sensors studied. This demonstrates that 
activation of the PKA enzyme by dbcAMP is sufficient to generate changes at distinct 
microdomains. 
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Figure 1.9| AMPH mediated PKA activation requires DAT. (A) HEK293 cells co–
expressing Mito–AKAR4 and DAT show increases in PKA activation (green lines). 
However, in cells that do not co–express DAT, AMPH (10 μM) treatment did not result in 
marked increased in PKA activation (black lines). This DAT–dependence is consistent 
with previously published data [10,13,19,21]. Maximum change in FRET emission ratio 
at 30 minutes was 117.45 ± 1.73 % for cells transfected with both DAT and Mito–
AKAR4 compared to 103.95 ± 0.85 % in the absence of DAT. (B) Analysis of the AUC 
indicates that AMPH–mediated PKA activation in the presence of DAT is significantly 
greater than without DAT co–expression.  (**** p ≤ 0.0001 by two–tailed parametric t–
test). (C) Representative single cell images of the FRET emission ratio changes in 
HEK293 cells. Top FRET YFP/CFP emission ratio in the absence of DAT and bottom 
FRET YFP/CFP in the presence of DAT at various time points. Scale bar, represents 10 
µm.  
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Figure 1.10| PKA–FRET biosensors do not show preferential responses to AMPH in 
HEK293 cells. (A) HEK293 cells expressing the four targeted AKAR4 sensors to the 
mitochondria, Golgi and synaptic vesicle membranes and the nucleus showed canonical 
localization and organelle morphology. (B) PKA activation by AMPH was detected in all 
organelle compartments. (C) Analysis of the area under the curves (AUC) followed by 
one–way ANOVA analysis compared to SV–AKAR4 showed no significant difference in 
activation by AMPH. (ns, statistically nonsignificant).  
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Figure 1.11| PKA activation in response to AMPH favors synaptic vesicles in SK–N–
SH cells. (A) SK–N–SH neuroblastoma cells co–transfected with DAT and different 
targeting AKAR4 sensors. The biosensors targeted to the mitochondria Golgi, synaptic 
vesicle, lipid–raft and non–raft membranes and the nucleus show canonical localization 
and organelle morphology. (B) PKA activation by AMPH was detected in all organelle 
compartments.  (C) Analysis of the AUC followed by one–way ANOVA analysis indicate 
that the synaptic vesicle targeted (SV–AKAR4, purple) PKA sensor is significantly 
activated in response to AMPH compared to all other compartments (**** p < 0.0001).  
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Figure 1.12 | RhoA–2 FRET biosensor. (A) Schematic of RhoA–2, a Rho–based 
intramolecular FRET sensor. The RhoA–2 plasmid construct for the intramolecular 
RhoA biosensor consists of the Rho–binding domain (RBD) of rhotekin, which binds to 
GTP–bound RhoA GTPase. The Rho–binding domain is separated from the donor CFP 
variant, mCerulean3 by a 2X glycine linker. mCerulean3 (blue) is a brighter third 
generation fluorophore [45]. An unstructured linker separates the acceptor YFP variant, 
mCitrine from mCerulean3 [45]. The mCitrine is separated from full length RhoA protein 
by another 2X glycine linker. The organelle targeting sequence motifs were added to the 
N–or C–terminus of the RhoA–2 plasmid. (B) Mechanism of intramolecular RhoA–2 
FRET emission. Conversion of inactive GDP–bound RhoA to activated GTP–bound 
RhoA by guanine exchange factors promotes the association of rhotekin with RhoA–
GTP, inducing a conformational change, which brings the donor CFP and YFP closer 
together resulting in increased FRET emission. This schematic is based on an original 
figure from Pertz et al. 2006 [45]. 
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Figure 1.13| Localization of MitoRhoA–2. (A) MitoRhoA–2 properly localizes to the 
mitochondrial compartment. In transfected HEK293 cells, MitoRhoA–2 is colocalized 
with the mitochondria specific dye, MitoTracker (red). Scale bar, 10 μm. (B) 
Mitochondrial fractions are enriched in MitoRhoA–2. HEK293 cells transiently 
transfected with the untargeted RhoA–2 plasmid or the MitoRhoA–2 reporter were 
fractionated and separated by SDS–PAGE gel electrophoresis followed by western blot 
analysis. RhoA–2 is enriched in the cytoplasmic fractions, C, and absent from the 
mitochondrial fractions, M. Non–transfected cells were used as a negative control.  
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Figure 1.14| GolgiRhoA–2 localizes to the Golgi apparatus. (A) GolgiRhoA–2 
colocalizes with GM130. Transiently transfected SK–N–SH cells were fixed and 
immunostained with the Golgi marker. Scale bar, 10 μm. (B) GolgiRhoA–2 is enriched in 
crude ER/Golgi microsomes. An equal amount of protein (30 µg per lane) from the 
ER/Golgi enriched fractions and whole cell lysates (inputs) prepared from HEK293 cells 
were analyzed by western blot. The purity of ER/Golgi fractions were assessed for the 
presence of GM130 (a Golgi marker) and the absence of GADPH (A cytosolic marker) 
and β-actin (a cytosolic marker).  
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Figure 1.15| NuclearRhoA–2 and SVRhoA–2 cellular distribution. (A) NuclearRhoA–
2 localizes to the nucleus. SK–N–SH neuroblastoma cells transiently transfected with 
NuclearRhoA–2 and stained with DAPI. Both NuclearRhoA–2 (green) and DAPI (blue) 
co–localize as indicated in the merged image. Scale bar, 10 µm. (B) SVRhoA–2 
expression resembles synaptic vesicle and VMAT2. SK–N–SH cells transfected with 
SVRhoA–2 (green) indicate that the sensor has a punctate (white arrows) distribution in 
the cell reminiscent of VMAT2 positive synaptic vesicles. Scale bar, 10 μm.  
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Figure 1.16| RhoA biosensor response to AMPH is most robust in the ER/Golgi 
membranes in HEK293 cells. (A) HEK293 cells co–transfected with DAT (unlabeled) 
and different targeting RhoA–2 sensors (green). The biosensors targeted to the 
mitochondria (MitoRhoA–2), Golgi (GolgiRhoA–2), synaptic vesicle (SVRhoA–2), and 
endoplasmic reticulum (ERRhoA–2) membranes and the nucleus (NuclearRhoA–2) were 
localized to the predicted compartments. (B) Steady state RhoA activation. Baseline 
RhoA–2 responses prior to pharmacological activation by AMPH were stable at 100 %. 
(C) RhoA–2 activation by AMPH was detected in all organelle compartments. HEK293 
cells were stimulated with AMPH (10 μM) at 2 minutes preceding baseline FRET 
recordings. (D) Analysis of the AUC indicates by one–way ANOVA analysis that the 
RhoA response to AMPH are greater in the Golgi (blue) and ER (red) compartments. 
(**** p < 0.0001 by one–way ANOVA compared to ER; ns, statistically nonsignificant). 
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Figure 1.17| AMPH–induced RhoA biosensor activity favors the ER/Golgi domains 
in SK–N–SH cells. (A) SK–N–SH neuroblastoma cells co–transfected with DAT and 
different targeting RhoA–2 sensors. All targeted biosensors showed canonical localization 
and organelle morphology when transfected in SK–N–SH cells. (B) RhoA activation by 
AMPH was detected in all organelle compartments. SK–N–SH cells were stimulated with 
AMPH (10 μM) at 2 minutes preceding basal FRET recordings. (C) AUC analysis 
indicates that TAAR1–mediated RhoA response to AMPH favors the Golgi (blue) and ER 
(red) compartments. (** p < 0.01 and **** p < 0.0001 by one–way ANOVA compared to 
both ER and Golgi compartments; ns, statistically nonsignificant).  
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Figure 1.18| RhoA Activation in response to AMPH is attenuated in TAAR1 KO 
SK–N–SH cells.  (A) Representative curves of targeted sensors response to AMPH in 
TAAR1 KO cells. CRISPR–Cas9 deletion of TAAR1 in SK–N–SH cells reduce AMPH–
induced RhoA activation in almost all organelle compartments transfected with DAT and 
respective RhoA sensors in comparison to wildtype SK–N–SH cells (Inset, from Figure 
1.17).  (B) Summary of AMPH stimulated RhoA Activation in TAAR1 KO cells. We 
compared the AUC of WT SK–N–SH cells in Figure 1.17C to data from three separate 
experiments in TAAR1 KO cells. The absence of TAAR1 significantly reduces RhoA 
activation response in almost all compartments and is most significant in the Golgi, ER 
and nuclear compartments. 
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CHAPTER TWO: INTRODUCTION   
 
VMAT Function and Location 
The integrity and strength of monoaminergic neurotransmission requires the 
coordination of several critical steps, including (1) synthesis of monoamines and their 
precursors in the cytoplasm; (2) loading of neurotransmitter (NT) synaptic vesicles where 
they are sometimes further modified; and (3) exocytosis from vesicles into the 
synapse[61–63]. Dysregulation in any of these steps presents in a myriad of neurological 
and neuropsychiatric disorders including schizophrenia, Parkinson’s and drug addiction 
[63]. A key determinant of synaptic neurotransmission and function is the availability of 
monoamines for storage and release by synaptic vesicles. In midbrain dopaminergic 
neurons, these processes are partly mediated by vesicular monoamine transporter 2, 
VMAT2, which belong to the Slc18 family of cation–dependent neurotransmitter 
transporters [64,65]. VMAT2 is a twelve–transmembrane pH and proton–ATPase–
dependent transporter responsible for storage and release of DA, serotonin, histamine and 
norepinephrine in the peripheral and central nervous system (PNS; CNS). For every 
substrate transported into the vesicle, two protons are pumped from the intravesicular 
space into the cytoplasm. Vesicular uptake of neurotransmitters prevents rapid 
degradation of monoamines  into toxic metabolites and neurotoxic oxidation [63–66].  
VMAT2 (Slc18a2) is structurally–related to VMAT1 (Slc18a1) but  the two 
transporters possess distinct pharmacological properties and distributions [67]. Both 
isoforms of VMAT are localized to large dense–core vesicles (LDCV) in the PNS. In the 
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mammalian  brain, however, VMAT2 is present in small synaptic vesicles (SSV) 
[62,65,68,69]. It is believed that VMAT1  is preferentially localized to LDCV of 
neuroendocrine cells in the PNS, while VMAT2 is thought to localize to both LDCV in 
the PNS and SSV in the CNS Recent evidence using high throughput sequencing, in situ 
hybridization and immunocytochemical studies suggest that VMAT1 is also present in the 
CNS, where it is concentrated to the SN and has been implicated in the etiology of 
schizophrenia [70–75].  
  
VMAT Regulation  
Our current understanding of VMAT2 regulation stems from the extent to which 
neurotoxic agents affect vesicular transport. VMAT2 is inhibited by psychotherapeutic 
drugs, stimulants and metabolites such as, reserpine (RES), tetrabenazine (TBZ), 
methamphetamine (METH), amphetamine (AMPH), and 1–methyl–4–phenyl–1,2,3,6–
tetrahydropyridine,  and MPTP a prodrug of the neurotoxin MPP+ [63,64,76,77]. AMPH 
and METH are transported inhibitors of VMAT2 while RES and TBZ are non–
transported inhibitors. Increased cytoplasmic METH and AMPH are transported by 
VMAT2 and promote the extrusion of vesicular DA into the cytoplasm thereby increasing 
cytosolic DA [63]. A consequence of increased cytosolic DA is the formation of toxic 
metabolites that are associated loss of DA neurons in diseases like Parkinson’s, and thus, 
it is of interest to elucidate the intracellular mechanisms by which VMAT2 transport is 
regulated.   
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We hypothesized that under normal physiological conditions, DA neurons that 
use VMAT2 for vesicular filling maybe self–regulated and that spillover of DA may 
provide a mechanism for the intracellular regulation of VMAT2. In DA neurons spillover 
from vesicular filling and increased cytosolic DA could initiate a signaling cascade that 
regulates VMAT2. TAAR1, which is activated by DA and leads to elevation in cyclic 
AMP (cAMP) could modulate VMAT2 activity. In 1995, Nakanishi and colleagues 
demonstrated that treatment of digitonin–permeabilized PC12 cells with dibutyrl cyclic 
AMP (dbcAMP), reduced VMAT2–mediated uptake [78], while PKA inhibitors increased 
VMAT2 uptake [78]. However, the receptors, intracellular signaling proteins and precise 
mechanism responsible for endogenous cAMP–dependent regulation of VMAT2 has not 
been addressed. It is also unclear whether a cAMP–dependent mechanism for regulation 
of VMAT2 occurs in neurons.  
VMAT2  and TAAR1 
Localization of TAAR1 in monoaminergic brain regions including the 
nigrostriatal and mesolimbic dopaminergic pathways that use the vesicular transporter, 
VMAT2, suggests that TAAR1 might be well positioned to regulate monoaminergic 
neurotransmission [7,10,13]. Given TAAR1’s intracellular location and its ability to 
increase cAMP, it is conceivable that TAAR1 could serve as a sensor of cytosolic 
monoamines and their metabolites to regulate VMAT2 activity. The present study seeks 
to examine whether TAAR1–mediated activation of GαS–AC–cAMP–PKA signaling can 
regulate VMAT2 function using three model cell lines that express VMAT2: SK–N–SH 
cells that express both VMAT2 and TAAR1, an SK–N–SH cell line in which CRISPR–
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Cas9 technology was used to knockout the endogenous TAAR1 protein gene and cultured   
murine midbrain DA neurons.  
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CHAPTER TWO: SPECIFIC AIMS 
As previously described, VMAT2 has been shown to be intracellularly regulated by 
activators of PKA like cAMP. However, the mechanism and upstream signaling 
molecules responsible for cAMP–dependent regulation of VMAT2 has not been 
described. The ability for TAAR1 to elevate cAMP, as well as, its co–expression with 
VMAT2 in DA neurons suggests that TAAR1–signaling may regulate VMAT2 function. 
Towards investigating this we address the following specific aims: 
1) To determine whether VMAT2 is regulated by PKA agonists like cAMP in 
SK–N–SH cells. 
2) To examine whether TAAR1 is essential for VMAT2 regulation by comparing 
the effects of TAAR1 activation on VMAT2 activity in wild type SK–N–SH 
cells to those observed an SK–N–SH line in which the TAAR1 gene is 
disrupted.  
The neuroprotective and vesicular filling roles of VMAT2 in the brain depend on its 
function in regulating cytoplasmic and vesicular catecholamine content, but the 
physiological intracellular mechanisms that work to regulate VMAT2 remain unclear. 
Therefore, knowledge from this study will provide new insight on intracellular regulation 
of VMAT2, towards understanding the consequence of VMAT2 dysregulation in disease.    
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MATERIALS & METHODS 
Materials 
Antibodies: Tyrosine hydroxylase (TH) polyclonal antibodies were acquired from AVES 
labs (anti–Chicken, Cat #TYH). Rabbit anti–VMAT2 antibody (cat# ab191121) was 
purchased from Abcam. DAT antibody was generated in house as previously described 
[19,21]. Secondary antibodies donkey anti–mouse HRP and donkey anti–rabbit HRP 
were acquired from Jackson Immuno Research Laboratories Inc (cat# 715–035–150) and 
Pierce (cat# 31458), respectively.  
 
Tritiated Neurotransmitters: [3H] Dopamine (3,4[7–3H] dihydroxyphenylethylamine) and 
[3H] 5–hydroxytryptamine (5–HT, serotonin) were both purchased from PerkinElmer 
Life and Analytical Sciences (Waltham, MA). 
  
Drugs and Toxins: Desipramine (cat# D3900), Mg2+ATP (cat #A9187), reserpine (cat# 
83580) and dibutyryl cAMP (cat# D026) were acquired from Sigma Aldrich Chemical 
Co (St. Louis, MO). Unlabeled serotonin (cat# H953), and DA hydrochloride (cat# 
H8502) were also acquired from Sigma Aldrich. GBR12909 dihydrochloride (cat# 0421), 
p–triflouromethoxyphenylhydrazone (FCCP, cat# 0453) and cAMPs–Rp, 
triethylammonium salt (cat# 1337), were purchased from Tocris (Ellisville, MO). PKA 
specific inhibitor KT5720 was acquired from A.G. Scientific (cat# K–1010). Reagents for 
SDS–PAGE, Bicinchoninic Bradford Protein Assay, Dulbecco's Modified Eagle’s 
Medium (DMEM), fetal bovine serum (FBS) and all other culture media components 
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were purchased from Invitrogen/Life Technologies. cOmplete™ Mini EDTA–free 
Protease Inhibitor Cocktail, (cat# 11836170001) was acquired from Roche Diagnostics 
(IN, USA).  
Methods: 
Primary Neurons: Primary DA neurons were prepared from midbrain tissue dissected 
from embryonic day15 (E15) Swiss Webster mice as previously described [21]. All 
procedures and experiments with mice were performed in accordance with the NIH 
Guide for the Care and Use of Laboratory Animals and with the approval of the 
Institutional Animal Care and the Animal Care and Use Committee of the NIH. Midbrain 
tissue was subsequently triturated and plated at a density of 2 midbrains per 6×25 mm or 
12×12 mm on poly–D–lysine coated glass coverslips (Warner Instruments). Cultures 
were maintained in DMEM supplemented with 5 % horse serum and 5 % calf serum for 
14 to 28 days before being used for each experiment.  
Cell Culture: SK–N–SH cells were obtained from ATCC (Rockville, MD, U.S.A.) and 
maintained in Dulbecco’s Modified Eagles Medium with 5 % FBS and 0.1 % 
Penicillin/Streptomycin (P/S) at 37 ºC in 5 % CO2. Cells were grown in 75 cm
2 flasks 
and later transferred to 96 well plates or plated on 12 mm poly–D–lysine (10 μg/mL) 
coated glass coverslips and allowed to proliferate to reach confluence prior to initiating 
experiments. All cell culture assays were performed on cultures from at least three 
different plating procedures. Where possible, experiments were performed blindly. 
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Knock Out Cell Line: The TAAR1 KO cell line (Appendix 2A) generated in Chapter I 
was all used in this study. See materials and methods in Chapter I for details.   
 
Vesicular Monoamine Uptake: SK–N–SH cells were plated in 96 well plates and primary 
DA neurons were plated on 12 mm glass coverslips. The cells were permeabilized with 
digitonin (10 µM, 10–15 minutes) in DMEM and then equilibrated in uptake PBSK+ buffer 
containing: 2.7 mM NaCl, 137 mM KCL, 10 mM Na2HPO4, 1.8 mM KH2PO4, 2.5 mM 
Mg2+–ATP, pH 7.5 and GBR12909 (10 µM). The cells were incubated with 10 μM 
reserpine for ten minutes, unless otherwise noted, and uptake assays were initiated by the 
addition of 20 µM unlabeled DA and 50–60 nM [3H]–DA in uptake buffer for 5 minutes 
at room temperature (RT). Uptake was terminated by two rapid washes with 50 μL PBS–
CM (PBS with 100 μM CaCl2 and 1 mM MgCl2). Cells were then solubilized in 50 μL of 
Bio–safe II scintillation fluid (RPI, Research Product International) and radioactivity was 
measured using a Microplate Liquid Scintillation Counter (model 2450 Perkin Elmer, 
MicroBeta2) or a LS 6500 Multipurpose Liquid Scintillation Counter (Beckman Coulter). 
In parallel, non–specific uptake of [3H]–DA or [3H] 5–HT was determined in the presence 
of GBR12909 (10 µM) and desipramine (100 nM) and subtracted from total uptake to 
calculate specific VMAT2–mediated uptake. Data analysis was performed using Prism 7.0 
(GraphPad Software Inc., San Diego, CA). Results are given as means ± SEM from more 
than three experiments performed in hexads on cells from different plating procedures.  
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Immunohistochemistry: Cells were fixed in 4 % paraformaldehyde at RT for 15 minutes. 
After three washes with phosphate–buffered saline (PBS), cells were permeabilized with 
0.20 % Triton X–100 for 5 minutes and blocked with 5 % normal goat serum (NGS) for 2 
h at room temperature before incubation with primary antibodies diluted in 5 % NGS 
overnight at 4 °C on a shaker. Primary antibodies were removed with three PBS washes 
and secondary antibodies applied in 5 % NGS at RT for 2 h. Secondary antibodies were 
washed off and coverslips were mounted in FluoromountTM Aqueous Mounting Medium 
(cat# F4680; Sigma Aldrich) for subsequent confocal microscopy.  
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RESULTS 
VMAT2 –mediated, reserpine sensitive uptake in midbrain DA neurons 
Midbrain (MB) DA neurons express the twelve–transmembrane vesicular 
monoamine transporter 2 (VMAT2), which regulates cytoplasmic catecholamine levels. 
DA synthesized by the cell and extracellular DA that is transported into the cytoplasm by 
the DAT is concentrated into vesicles by VMAT2 in a proton and ATP–dependent 
manner. Preliminary data from the Amara laboratory demonstrated that both DAT and 
VMAT2 are expressed in MB DA neurons in culture (Figure 2.1A). To assess VMAT2 
specific function, we exploited the VMAT2 inhibitory ligand reserpine [79,80]. 
Digitonin–permeabilized primary neurons were pre–incubated with a buffer mimicking 
the intracellular environment, the DAT inhibitor GBR12909 and ATP (required for 
VMAT2 uptake) in the presence or absence of reserpine. GBR12909 was added to ensure 
that we were measuring VMAT2–specific uptake and not DAT–mediated uptake in 
incompletely permeabilized cells. Following preincubation with reserpine, 20 µM of 
unlabeled DA and 50 nM [3H]–DA was added to the neurons for 5 minutes at RT. 
Reserpine potently reduced VMAT2 uptake greater than 70 % of control (p < 0.0001) and 
required the presence of ATP (Figure 2.1B). In addition, disruption of the pH gradient 
and increased proton (H+)–permeability of the synaptic vesicle lipid bilayer by protein–
independent uncoupler, carbonyl cyanide p–trifluoromethoxyphenylhydrazone (FCCP) 
also blocked reserpine–sensitive VMAT2–mediated DA uptake (Figure 2.1B).  
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PKA Stimulation regulates VMAT2 sensitive DA uptake in midbrain neurons 
Endogenous DA spillover from maximal vesicular filling might be a physiological 
self–regulator of VMAT2 transport. To date, intracellular regulation of VMAT2 has not 
been fully described. We hypothesized that protein kinase A, PKA, may serve as an 
intracellular regulator of VMAT2 in DA neurons. To test this hypothesis, we conducted 
VMAT2 –mediated uptake assays on MB DA cultures in the presence of commercially 
available PKA agonists and antagonists. Treatment of MB DA neurons with dibutyryl 
cAMP, a cell permeable analogue of cAMP, to activate PKA resulted in decreased 
reserpine–sensitive [3H]–DA VMAT2 uptake (52.55   9.86 %; n = 12) in vitro compared 
to control (Figure 2.1C). Similarly, activation of adenylyl cyclase with forskolin 
generated a dramatic decrease in VMAT2 uptake, 53.7  9.34 % (n = 14) of vehicle 
control. Conversely, treatment of MB DA neurons with a selective allosteric PKA 
inhibitor, KT 5720, and RpcAMPs an inhibitor of cAMP resulted in a significant increase 
in VMAT2–mediated uptake in vitro (p < 0.01 and p < 0.001 respectively; Figure 2.1C). 
These data indicate that PKA negatively regulates VMAT2 activity in DA neurons and 
that upstream signaling protein(s) and receptor(s) may be important for initiating this 
pathway. We hypothesized that activation of a GPCR by DA that stimulates cAMP 
elevation like TAAR1, or the dopamine receptor 1 (DRD1) could act as sensors to 
regulate cytoplasmic DA and synaptic vesicle filling by VMAT2 (Figure 2.1D). 
Furthermore, activation of TAAR1–GαS–AC–cAMP–PKA signaling by high cytoplasmic 
DA may induce downregulation of VMAT2–mediated uptake (Figure 2.1D). 
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Blocking GαS increases reserpine–sensitive VMAT2–mediated uptake 
AC may be activated by several stimuli including the Gα stimulatory G–protein 
(GαS) resulting in the activation of PKA. DRD1 and TAAR1 are two GPCRs that are 
integral and requisite for maintaining function of DA neurons [7,81]. Activation of both 
receptors leads to activation of GαS G–proteins and elevation of intracellular cAMP. To 
assess whether cAMP–dependent modulation of VMAT2 in MB DA neurons is mediated 
by a GPCR we used a variety of α–subunit interfering peptides. The Gα specific 
inhibitors (Figure 2.2A) were generated by the fusion of the cell permeable peptide 
sequence of HIV transactivator (TAT, 47–57) protein (GRKKRRQRRRPQ) and alpha 
interfering mini–gene sequences [82,83]. These interfering peptides block specific alpha 
subunits of heterotrimeric G–protein complexes preventing them from being activated by 
GPCRs and guanine nucleotide exchange factors (Figure 2.2A). Treatment of primary 
cultures with Gα13 (TAT–13) and Gαs (TAT–R Control) interfering peptides did not 
affect reserpine–sensitive VMAT2–mediated uptake (Figure 2.2A). However, inhibition 
of GαS by TAT–S resulted in increased reserpine–sensitive VMAT2–mediated 3H–DA 
uptake. TAT–S increased vesicle contents of DA by 210.8 ± 38.3 %; n = 6 (p value ≤ 
0.0130) over control (Figure 2.2A).  
The observed increase in VMAT2 uptake in response to the inhibition of GαS 
suggests that the stimulation of a GPCR that signals through the GαS pathway is 
responsible for cAMP–mediated VMAT2 regulation. We next examined the potential of 
DRD1 receptors to modulate VMAT2 activity. Blocking DRD1 receptors with D1/D2 
antagonists did not affect TAT–S induced reserpine–sensitive VMAT2–mediated uptake 
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(Figure 2.2B). Since TAAR1 has also been shown to activate the GαS pathway [1,2], we 
hypothesized that this GPCR may serve as an intracellular DA sensor. The presence of 
TAAR1 and VMAT2 in SK–N–SH cells as well as the robust DA uptake capacity of 
these cells, compelled us to evaluate whether inhibition of VMAT2 uptake by 
cAMP/PKA could be observed in SK–N–SH TAAR1 knockout cell lines.  
Time course of the effect of reserpine on VMAT2 [3H]–DA uptake 
The time course of the effect of reserpine (10 μM) on [3H]–DA uptake in SK–N–
SH cells was determined. SK–N–SH cells were pre–incubated with reserpine followed by 
the addition of [3H]–DA. VMAT2–mediated uptake was significantly reduced (53.33 ± 
6.68 %; n = 9) after 10 min of pre–incubation (Figure 2.3). Note that reserpine was also 
present during the uptake assay. Exposure of SK–N–SH cells to reserpine for 30 minutes 
decreased [3H]–DA uptake to 37.59 ±8.89 % (n =10) of control (Figure 2.3), which was 
similar to the VMAT2 uptake observed in the absence of digitonin permeabilization 
(38.98 ± 3.23 % (n =10) of control) indicating that reserpine sensitive, VMAT2–mediated 
uptake can successfully be measured in these cells using this method. 
 
Characterization of SK–N–SH TAAR1 knockout cell line  
SK–N–SH cells express TAAR1 and VMAT2 and form functional 
neurotransmitter vesicles reminiscent of the small synaptic vesicles (SSV) found in 
neurons (Figure 2.4). CRISPR–Cas9 technology was used to generate the TAAR1 
knockout SK–N–SH cell line (See Appendix 2A). TAAR1 deletion did not affect the 
cellular morphology of the SK–N–SH cells (Figure 2. 4A). Both wild–type SK–N–SH 
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and the TAAR1 knockout cell lines express the VMAT2 protein as evidenced by western 
blot analysis and immunohistochemistry, respectively (Figures 2.4B, C).  
cAMP–dependent regulation of VMAT2 is not TAAR1 dependent 
To determine whether the cAMP–induced reduction in VMAT2 function observed 
in MB neurons was dependent on the TAAR1–GαS –AC–cAMP–PKA signaling 
pathway, we compared the effect of PKA on VMAT2 uptake in TAAR1 KO cell lines. 
There was no observed difference in uptake between wildtype SK–N–SH cells and 
TAAR1 KO cells treated with dbcAMP, forskolin, RpcAMPs or KT5720 drugs (Figure 
2.5A). VMAT2–mediated serotonin (5–HT) uptake which is a more effective substrate for 
VMAT2 (DA, KI = 25 ±7 μM vs. 5–HT, KI = 19 ±4 μM) [63], and less effective agonist 
of TAAR1 [2] also resulted in no change in sensitivity to cAMP modulation (Figure 
2.5B). These data indicate that in SK–N–SH cells cAMP downregulation of VMAT2 
activity is not mediated by TAAR1.  
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DISCUSSION 
The pathologies of addiction, schizophrenia and Parkinson’s disease all indicate 
dysregulation of catecholamine filling, storage and release by synaptic vesicles in the 
dopaminergic pathways of the brain [63,84]. As VMAT2 is a key regulator of 
catecholamine storage and release in the DA neuron, it is of interest that we understand 
the physiological mechanisms that regulate VMAT2. A mechanism that regulates filling 
of neuronal synaptic vesicles by VMAT2 and their transmitter content has not clearly 
been identified. Over–twenty years ago, a Japanese laboratory first demonstrated that the 
secondary messenger cAMP regulates the function of VMAT2 transport in endocrine 
derived pheochromocytoma (PC 12) cells [78,85]. These data implicated cAMP as an 
intracellular regulator of vesicular transport and filling by VMAT2. However, the 
intracellular protein effectors affecting cAMP modulation of VMAT2 activity have not 
been explored. Furthermore, it is unclear whether this mechanism of cAMP–dependent 
VMAT2 regulation is present in neuronal vesicles and cells. We report here that in two 
cell lines and primary cultures that cAMP can serve as an intracellular regulator of 
VMAT2 activity. Further, we have evaluated the role of the D1DR1 and TAAR1 in this 
signaling pathway. Our data supports that GαS coupled GPCRs may be involved in 
cAMP–dependent regulation of VMAT2 since inhibition of GαS  G–proteins resulted in a 
marked increase in VMAT2 transport as compared with control groups. As both GPCR’s 
are activated by DA which leads to increases in cAMP, it is possible that under normal 
conditions spillover of DA above normal vesicular filling capacity may trigger a VMAT2 
regulation cascade.  
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Nakanishi and colleagues evaluated the effect of cAMP on vesicular monoamine 
transport in large dense core vesicles (LDCV) present in PC12 cells in the PNS. 
However, we chose to study SK–N–SH cells which contain small synaptic vesicles 
(SSV), and better model the synaptic vesicles responsible for neurotransmitter storage in 
neurons of the CNS [62,69]. Additionally, MB DA neuronal cultures also express 
VMAT2 in SSV. Therefore, both SK–N–SH and MB DA neuronal cultures provide a 
better model system to further explore cAMP–dependent regulation of VMAT2 in the 
brain. We sought to ask the following questions: [1] Can cAMP also regulate VMAT2 
uptake in MB DA neurons and SK–N–SH cells? [2] Does blocking the α–subunit of GαS 
heterotrimeric G–proteins modulate vesicular monoamine transport? and [3] Which GαS 
coupled GPCR can serve as an intracellular sensor of monoamines and subsequent 
regulation of VMAT2? 
Herein, we developed a system for measuring VMAT2–mediated, reserpine–
sensitive DA uptake in primary neurons and SK–N–SH cells. In these cell systems 
VMAT2 activity is sensitive to treatment with reserpine and cAMP in the presence of 
ATP. Both dbcAMP and forskolin, are similarly effective at downregulating VMAT2 
activity. In MB DA neurons and SK–N–SH cells cAMP–dependent reduction in VMAT2 
uptake is consistent with previous reports in PC12 cells [78]. Further, the protein kinase 
inhibitor, KT 5720, and the cAMP inhibitor, RpcAMPs, resulted in increased vesicular 
DA uptake suggesting that cAMP–sensitive protein phosphorylation via the PKA 
pathway may regulate VMAT2 uptake. 
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PKA activation can be mediated via activation of the GαS–AC–cAMP pathway.  
Using a variety of α–subunit specific inhibitors we showed that cAMP–dependent 
modulation of VMAT2 in MB DA neurons was mediated by GαS signaling. Inhibition of 
DRD1 using DRD1/2 antagonists to block DRD1–Gαs–AC–cAMP signaling did not 
affect TAT–S induced increase in VMAT2 sensitive transport of DA in MB DA neurons 
in vitro. Activation of GαS coupled TAAR1 receptors by DA increases cAMP. TAAR1 
knockout SK–N–SH cells were used to implicate TAAR1 in cAMP–dependent regulation 
of VMAT2. Treatment of both cell lines with cAMP analogues lead to downregulation of 
vesicular monoamine transport while treatment with kinase inhibitors led to increased 
vesicular uptake suggesting that TAAR1 does not mediate cAMP–dependent regulation 
of VMAT2. Serotonin, a higher affinity substrate for VMAT2 and less potent agonist of 
TAAR1 resulted in no observed difference uptake in both cells lines.  
The regulation of VMAT2 by G–proteins is a complex phenomenon that may 
change dependent on cellular requirements and cell type. Different cell types may have a 
different array of intracellular signaling machinery to regulate VMAT2 function. For 
example, Anhert and colleagues reported that GαO2 and Gαq activity downregulate 
VMAT1&2 –mediated transport in neuroendocrine cells and VMAT2 in neurons [86–88]. 
GαO2 also regulates the vesicular glutamate transporters  by modulating its chloride 
dependence [89] suggesting a mechanism by which this regulation could occur.  
cAMP–dependent protein phosphorylation of tyrosine hydroxylase (TH), the rate–
limiting enzyme in catecholamine biogenesis, enhances TH activity and monoamine 
synthesis [90,91]. One could speculate that the observed cAMP–dependent reduction in 
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VMAT2 DA uptake was caused by increased intracellular DA synthesis due to increased 
TH activity. In effect, increased TH activity could increase endogenous DA 
concentrations, which may compete with [3H]–DA during uptake. The uptake assay 
contained 20 μM of unlabeled DA which is 500–fold greater that the 60 nM of 
radiolabeled DA used for uptake, indicating that TH upregulation and dilution of the 
radiolabel is unlikely to account for the reduced VMAT2 DA uptake.  cAMP treatment 
resulted in a similar reduction of VMAT2 serotonin uptake (Figure 2.6B), which is 
independent of TH activity and has a higher affinity for VMAT2 than DA (DA, KI = 25 
±7 μM; 5–HT, KI = 19 ±4 μM) [63,92,93]. However, to completely rule out the effect of 
TH on VMAT2 activity, in the presence of cAMP more experiments will be conducted. 
Further, we will look at the effects of cAMP in the presence of a TH inhibitor like alpha 
methyl–p–tyrosine. 
 In summary, we have shown that cAMP/PKA reduces reserpine–sensitive 
VMAT2 mediated DA uptake in MB DA neurons and SK–N–SH cells. Further, inhibition 
of endogenous GαS signaling abolished reserpine–sensitive VMAT2 DA uptake in MB 
neurons in vitro. We explored whether GαS coupled DRD1 or TAAR1 were responsible. 
Inhibition of DRD1 by D1/D2 antagonist and GαS inhibitory peptides did not attenuate 
reserpine–sensitive VMAT2 activity in MB DA neurons. In SK–N–SH cells lacking 
TAAR1 no difference in VMAT2 uptake is observed when treated with cAMP or PKA 
antagonists. These data indicate that neither DRD1 nor TAAR1 mediates GαS or cAMP–
dependent regulation of VMAT2 activity.  
 66 
Our current understanding of VMAT2 focuses on its regulation by physiological 
stressors and drugs [84]. For example, in the brain this is especially the case in the 
dopaminergic neurons where drugs of abuse alter dopamine availability in the synapse 
and cytoplasm. Some of these changes in cytoplasmic and synaptic dopamine are in part 
regulated by VMAT2. Therefore, understanding the physiological mechanisms governing 
VMAT2 DA transport and storage is of interest. Our findings herein, provide evidence for 
cAMP–dependent regulation of VMAT2 in DA neurons and suggests that under normal 
physiological circumstances elevated cytoplasmic DA and/or GαS signaling may be 
responsible for initiating this signaling cascade. In effect, our data provides a basis 
intracellular regulation of VMAT2. Further exploration of this work could expand our 
understanding of VMAT2 regulation and may provide insight into how VMAT2 
dysregulation manifests in disorders like drug addiction schizophrenia, and Parkinson’s. 
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Figure 2.1: cAMP–dependent downregulation of VMAT2 activity in MB DA 
neurons. (A) VMAT2 expression in MB Dopamine neurons is confirmed by 
immunolabeling. Midbrain DA neurons were grown in culture and stained for tyrosine 
hydroxylase (TH; green in a, and c), DAT (red, b) and VMAT2 (red, d). Scale bar, 10 µm. 
(B) Reserpine–sensitive VMAT2 uptake is dependent on ATP and pH. Digitonin 
permeabilized MB DA cultures were treated with reserpine, in the presence or absence of 
ATP and FCCP. Reserpine (10 μM) reduced VMAT2–mediated uptake by 60 %. In the 
absence of ATP, [3H]–DA uptake was reduced to 80 % of controls. FCCP, which disrupts 
the pH gradient in SVs, also decreased [3H]–DA uptake further supporting that this is 
VMAT2–mediated [3H]–DA uptake. (C) cAMP regulates vesicular VMAT2 uptake. 
Midbrain DA neurons were treated with reserpine, dbcAMP, forskolin, RpcAMPs or KT 
5720 prior to and during uptake measures. The data shown represent mean ± SEM of 
three or more experiments. (* p ≤ 0.05; ** p ≤ 0.01 and **** p ≤ 0.0001 by one–way 
ANOVA compared to vehicle control). (D) Schematic of proposed TAAR1 mediated, 
cAMP–dependent regulation of VMAT2. Vesicular filling above normal capacity could 
lead to DA spillover and subsequent activation of TAAR1 or DRD1 and elevation in 
cAMP which inhibit VMAT2 transport.  
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Figure 2.2: GαS G–proteins downregulate reserpine–sensitive VMAT2 uptake. (A) 
Amino acid alignment of specific Gα inhibitory interfering peptides. Cell permeable 
interfering peptides were generated in the Amara lab by the fusion of these thirteen amino 
acid peptides to the TAT peptide [82,83]. The specific family of Gα proteins which the 
peptide targets is also shown. GαR was used as scrambled control. (B) Inhibition of GαS 
increases VMAT2 uptake. MB DA neurons were treated with cell permeable alpha–
interfering peptides. In cells treated with TAT–S, VMAT2 uptake was increased in 
comparison to that observed in the presence of the TAT–R and TAT–13 alpha interfering 
peptides. (C) Blocking DRD1 receptor does not abolish TAT–S induced increased in 
VMAT2 uptake. Midbrain DA neurons were treated with D1/D2 receptor antagonists prior 
to treatment with cell permeable alpha–interfering peptides. In cells treated with TAT–S, 
blocking of DRD1 did not abolish TAT–S induced increased VMAT2 uptake. TAT–R and 
TAT–13 control interfering peptides did not increase VMAT2 activity. The data shown 
represents mean ± SEM of three or more experiments. (* p ≤ 0.05; ** p ≤ 0.01 and *** p 
≤ 0.001 by one–way ANOVA).  
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Figure 2.3: Time course of reserpine inhibition of VMAT2 DA uptake in SK–N–SH 
cells. Digitonin–permeabilized cells were treated with reserpine for increasing amounts 
of time. After 10 minutes of exposure reserpine significantly reduced uptake by VMAT2 
to 50% of the vehicle control, indicating that this is a sufficient time–point for reserpine 
to diffuse into the permeabilized cells and inhibit VMAT2–mediated DA uptake. All data 
points are represented as an average ± SEM. Quantification was performed on four 
independent experiments. (* p ≤ 0.05; ** p ≤ 0.01 and *** p ≤ 0.001 by one–way 
ANOVA; ns, statistically nonsignificant). 
 
 
V
e
h
ic
le
 5
1
0
2
0
3
0
0
5 0
1 0 0
1 5 0
3
H
-D
o
p
a
m
in
e
 U
p
ta
k
e
,
%
 V
e
h
ic
le
 C
o
n
tr
o
l
***
***
V e h ic le
5
10
20
30
E x p o s u re  T im e  (m in )
ns
 70 
 
 
Figure 2.4: Deletion of TAAR1 does not change the morphology of the cells or the 
expression of VMAT2. (A) Wildtype SK–N–SH cells and TAAR1 KO K–SN–SH cells 
have similar morphology as evidenced by DIC image. (B) Equal amounts of cell lysates 
from the wild–type (WT) and TAAR1 KO cells were analyzed by western blot for 
VMAT2. Both cell types contain VMAT2. β–actin further confirms similar protein 
concentrations in the two samples. (C) SK–N–SH cells express VMAT2 and tyrosine 
hydroxylase (TH).   
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Figure 2.5: TAAR1 does not mediate cAMP–dependent VMAT2 uptake in SK–N–
SH cells. (A) cAMP–dependent VMAT2 DA uptake. Digitonin–permeabilized WT and 
TAAR1 KO cells were treated with reserpine, dbcAMP, forskolin and RpcAMPs. 
Reserpine significantly reduced VMAT2 DA uptake in both cell types. Forskolin and 
dbcAMP decreased VMAT2   DA uptake while, inhibition of PKA by RpcAMPs 
increased VMAT2 DA transport. In comparison WT, no difference in cAMP–dependent 
downregulation in VMAT2 activity is present. (B) cAMP–dependent VMAT2 serotonin (5–
HT) uptake. Using 5–HT, we observed similar data. All data in bar graphs are presented 
as average ± SEM from three or more independent experiments. (**** p ≤ 0.0001 by 
two–way ANOVA; ns, statistically nonsignificant).  
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APPENDIX 
 
 
 
Appendix 1A| eNOSAKAR4 does not colocalize with trans–Golgi marker Golgin–97. 
Post transfection of HEK293 cells with eNOSAKAR4, the cells were stained with mouse 
monoclonal Golgin–97 antibody. Merged image show that GFP and Alexa 568 (Golgin–
97) do not colocalize. In addition, the eNOSAKAR4 also shows noticeable cytoplasmic 
expression. Scale bar, 10 µm.  
 
 
Appendix 2A| Development of CRISPR–Cas9 TAAR1 knockout SK–N–SH cell line.                         
(A) Sequence alignment of the wildtype (WT) and knockout (KO) TAAR1 cDNA. The 
Cas9 endonuclease required photospacer adjacent motif (PAM) sequence indicated by the 
blue line caused the deletion of a cytosine nucleotide (red arrow), which resulted in a 
frameshift that generated a premature stop codon (red line). (B) Truncated TAAR1 KO 
Protein Sequence. The translation of the TAAR1 KO gene generates a truncated and 
twenty–six amino acid TAAR1 peptide. The TAAR1 KO Cells were provided by Dr. 
Jingshan Chen in the Amaralab. Scale bar, 10 µm. 
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Appendix 3A| AKAR4 donor plasmid cellular distribution. The AKAR4 only plasmid 
shows whole cell distribution.  
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